IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes.
Cytokines
Glial cells
T cell motility
T lymphocytes
Transcription factors
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
01 Sep 2022
01 Sep 2022
Historique:
received:
17
05
2022
accepted:
23
08
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
8
9
2022
Statut:
epublish
Résumé
Interleukin-27 (IL-27) can trigger both pro- and anti-inflammatory responses. This cytokine is elevated in the central nervous system (CNS) of multiple sclerosis (MS) patients, but how it influences neuroinflammatory processes remains unclear. As astrocytes express the receptor for IL-27, we sought to determine how these glial cells respond to this cytokine and whether such exposure alters their interactions with infiltrating activated T lymphocytes. To determine whether inflammation shapes the impact of IL-27, we compared the effects of this cytokine in non-inflamed and inflamed conditions induced by an IL-1β exposure. Transcriptomic analysis of IL-27-exposed human astrocytes showed an upregulation of multiple immune genes. Human astrocytes increased the secretion of chemokines (CXCL9, CXCL10, and CXCL11) and the surface expression of proteins (PD-L1, HLA-E, and ICAM-1) following IL-27 exposure. To assess whether exposure of astrocytes to IL-27 influences the profile of activated T lymphocytes infiltrating the CNS, we used an astrocyte/T lymphocyte co-culture model. Activated human CD4 Our results establish that IL-27 alters the immune functions of human astrocytes and shapes the profile and motility of encountered T lymphocytes, especially CD8
Sections du résumé
BACKGROUND
BACKGROUND
Interleukin-27 (IL-27) can trigger both pro- and anti-inflammatory responses. This cytokine is elevated in the central nervous system (CNS) of multiple sclerosis (MS) patients, but how it influences neuroinflammatory processes remains unclear. As astrocytes express the receptor for IL-27, we sought to determine how these glial cells respond to this cytokine and whether such exposure alters their interactions with infiltrating activated T lymphocytes. To determine whether inflammation shapes the impact of IL-27, we compared the effects of this cytokine in non-inflamed and inflamed conditions induced by an IL-1β exposure.
MAIN BODY
METHODS
Transcriptomic analysis of IL-27-exposed human astrocytes showed an upregulation of multiple immune genes. Human astrocytes increased the secretion of chemokines (CXCL9, CXCL10, and CXCL11) and the surface expression of proteins (PD-L1, HLA-E, and ICAM-1) following IL-27 exposure. To assess whether exposure of astrocytes to IL-27 influences the profile of activated T lymphocytes infiltrating the CNS, we used an astrocyte/T lymphocyte co-culture model. Activated human CD4
CONCLUSION
CONCLUSIONS
Our results establish that IL-27 alters the immune functions of human astrocytes and shapes the profile and motility of encountered T lymphocytes, especially CD8
Identifiants
pubmed: 36050707
doi: 10.1186/s12974-022-02572-1
pii: 10.1186/s12974-022-02572-1
pmc: PMC9434874
doi:
Substances chimiques
B7-H1 Antigen
0
Cytokines
0
Interleukin-27
0
Interleukins
0
MYDGF protein, human
0
Intercellular Adhesion Molecule-1
126547-89-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Subventions
Organisme : Multiple Sclerosis Society of Canada
ID : EGID 1584
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : RGPIN 0476
Informations de copyright
© 2022. The Author(s).
Références
Brain. 1994 Feb;117 ( Pt 1):59-69
pubmed: 7511974
Cell Commun Signal. 2011 Apr 08;9:7
pubmed: 21477291
Trends Mol Med. 2018 Nov;24(11):950-962
pubmed: 30314877
Front Immunol. 2019 Oct 18;10:2436
pubmed: 31681316
Cell Mol Life Sci. 2013 Dec;70(24):4795-808
pubmed: 23892891
J Neurol Sci. 2005 May 15;232(1-2):3-9
pubmed: 15850576
Stem Cell Reports. 2018 Nov 13;11(5):1199-1210
pubmed: 30409508
Trends Mol Med. 2018 Jul;24(7):642-653
pubmed: 29880309
Brain. 2018 Jul 1;141(7):2066-2082
pubmed: 29873694
J Cell Biol. 2005 Jul 4;170(1):141-51
pubmed: 15983060
Mult Scler. 2010 Sep;16(9):1056-65
pubmed: 20354066
J Neuroinflammation. 2010 Jan 29;7:9
pubmed: 20113500
Immunity. 2012 Dec 14;37(6):960-9
pubmed: 23244718
Methods Mol Biol. 2019;1930:1-9
pubmed: 30610592
Nat Immunol. 2006 Sep;7(9):946-53
pubmed: 16906165
Eur J Immunol. 2008 May;38(5):1204-14
pubmed: 18412165
Adv Biol (Weinh). 2021 Sep;5(9):e2100758
pubmed: 34170628
J Exp Med. 2013 Apr 8;210(4):757-74
pubmed: 23530125
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15047-52
pubmed: 14657353
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Glia. 2011 May;59(5):841-56
pubmed: 21360758
J Neuroinflammation. 2017 Jul 24;14(1):144
pubmed: 28738904
PLoS One. 2014 Apr 01;9(4):e92325
pubmed: 24691121
Front Immunol. 2021 Apr 22;12:668483
pubmed: 33968073
Glia. 2016 Apr;64(4):553-69
pubmed: 26649511
J Clin Invest. 2014 May;124(5):2009-22
pubmed: 24713654
J Immunol. 2016 Nov 15;197(10):3831-3840
pubmed: 27798164
J Biol Chem. 2004 Jul 16;279(29):30219-27
pubmed: 15150261
Nat Rev Immunol. 2019 Jun;19(6):398-410
pubmed: 30846856
J Immunol. 2007 Jan 15;178(2):851-7
pubmed: 17202346
J Neuroimmunol. 2007 Jan;182(1-2):124-34
pubmed: 17182110
Front Immunol. 2016 Sep 27;7:382
pubmed: 27729910
Immunity. 2019 Apr 16;50(4):851-870
pubmed: 30995503
Autoimmun Rev. 2015 Dec;14(12):1131-1141
pubmed: 26253381
Brain Pathol. 2004 Jan;14(1):43-50
pubmed: 14997936
Sci Rep. 2017 Sep 14;7(1):11612
pubmed: 28912605
J Immunol. 2006 Mar 15;176(6):3480-9
pubmed: 16517716
Trends Immunol. 2020 Sep;41(9):758-770
pubmed: 32819810
J Immunol. 2001 Dec 15;167(12):7084-93
pubmed: 11739530
Immunol Cell Biol. 2012 Sep;90(8):831-5
pubmed: 22430249
J Neuroimmunol. 2019 Jul 15;332:112-125
pubmed: 31005712
Ann Clin Transl Neurol. 2015 Jun;2(6):609-22
pubmed: 26125037
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 29358320
Eur J Immunol. 2011 Jan;41(1):47-59
pubmed: 21182076
Front Immunol. 2018 May 03;9:952
pubmed: 29774029
J Interferon Cytokine Res. 2003 Sep;23(9):513-22
pubmed: 14565860
J Virol. 1996 Feb;70(2):1143-53
pubmed: 8551575
Front Immunol. 2022 Feb 08;13:824411
pubmed: 35211120
J Exp Med. 2021 Sep 6;218(9):
pubmed: 34292315
Nat Immunol. 2020 Apr;21(4):442-454
pubmed: 32152508
J Immunol. 2000 Sep 15;165(6):3099-104
pubmed: 10975822
Autoimmunity. 1994;19(1):15-22
pubmed: 7749038
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
J Neuroimmunol. 1994 Oct;54(1-2):129-44
pubmed: 7523443
Nat Rev Immunol. 2017 Jan;17(1):49-59
pubmed: 27916979
Annu Rev Immunol. 2015;33:417-43
pubmed: 25861977
Annu Rev Immunol. 2001;19:423-74
pubmed: 11244043
Neurology. 1995 Jun;45(6 Suppl 6):S16-21
pubmed: 7540265
J Immunol. 2014 Jun 1;192(11):5382-9
pubmed: 24771852
Brain Res. 2015 Oct 14;1623:63-73
pubmed: 25813828
Clin Transl Immunology. 2021 Mar 05;10(3):e1262
pubmed: 33728050
Acta Neuropathol. 2019 May;137(5):757-783
pubmed: 30847559
J Immunol. 2004 Feb 15;172(4):2225-31
pubmed: 14764690
FEBS J. 2018 Mar;285(5):809-827
pubmed: 29032605
J Neuroinflammation. 2020 Nov 26;17(1):357
pubmed: 33243290
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6873-8
pubmed: 10359806